CanSino jumps as NMPA grants priority review status to infant vaccine application

Cansino Biologics

10/02/2025 06:17

** Hong Kong shares of vaccine producer CanSino Biologics
Inc  6185.HK  jump 7% to HK$32.20, their highest since Jan. 6,
and on track for sixth straight session of gain
    ** Stock on track for the biggest one-day pct gain since
Nov. 11, 2024
    ** Shanghai-listed stock  688185.SS  climbs 3.5% to 63.66
yuan, high since Dec. 31, 2024
    ** CanSino said China's National Medical Products
Administration (NMPA) granted priority review status to the
firm's new drug application (NDA) for its absorbed diphtheria,
tetanus and acellular pertussis combined vaccine for infants
below 2 years 
    ** NMPA will prioritize resource allocation for the review
of NDAs, included in the scope of priority review and approval -
co
    ** Hong Kong's healthcare index  .HSCIH  rises 1.4%,    
Hang Seng Index  .HSI  surges 1.7%
    ** Hong Kong stock rose 33.8% last year, while
Shanghai-listed shares fell 18.1%  

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))